Journal article
Reduction of Chlamydia pecorum and Koala Retrovirus subtype B expression in wild koalas vaccinated with novel peptide and peptide/recombinant protein formulations
Vaccine: X, Vol.14, pp.1-9
2023
PMCID: PMC10422670
PMID: 37577264
Abstract
Koalas are an endangered species under threat of extinction from several factors, including infections agents. Chlamydia pecorum infection results in morbidity and mortality from ocular and urogenital diseases while Koala Retrovirus (KoRV) infection has been linked to increased rates of cancer and chlamy-diosis. Both C. pecorum and KoRV are endemic in many wild Australian koala populations, with limited treatment options available. Fortunately, vaccines for these pathogens are under development and have generated effective immune responses in multiple trials. The current study aimed to improve vaccine formulations by testing a novel peptide version of the Chlamydia vaccine and a combination Chlamydia – KoRV vaccine. Utilising a monitored wild population in Southeast Queensland, this trial followed koalas given either a 'Chlamydia only' vaccine (utilising four peptides from the chlamydial Major Outer Membrane Protein, MOMP), a combination 'Chlamydia and KoRV' vaccine (comprised of the chlamydial peptides plus a KoRV recombinant envelope protein (rEnv)) or no treatment. Clinical observations, C. pecorum and KoRV gene expression, serum IgG, and mucosal immune gene expression were assessed over a 17-month period. Overall, both vaccine formulations resulted in a decrease in chlamydiosis mortality, with decreases in C. pecorum, CD4, CD8b and IL-17A gene expression observed. In addition, the combination vaccine group also showed an increase in anti-KoRV IgG production that corresponded to a decrease in detected KoRV-B expression. While these results are favourable, the chlamydial peptide vaccine did not appear to outperform the established recombinant chlamydial vaccine and suggests that a combination vaccine formulated with recombinant MOMP plus KoRV rEnv could capitalize on the demonstrated benefits of both for the betterment of koalas into the future.
Details
- Title
- Reduction of Chlamydia pecorum and Koala Retrovirus subtype B expression in wild koalas vaccinated with novel peptide and peptide/recombinant protein formulations
- Authors
- Bonnie Quigley (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationPeter Timms (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationSharon Nyari (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationPhilippa McKay (Author) - Endeavour Veterinary Ecology Pty LtdJon Hanger (Author) - Endeavour Veterinary Ecology Pty LtdSamuel Phillips (Corresponding Author) - University of the Sunshine Coast, Queensland, Centre for Bioinnovation
- Publication details
- Vaccine: X, Vol.14, pp.1-9
- Publisher
- Elsevier Ltd
- Date published
- 2023
- DOI
- 10.1016/j.jvacx.2023.100329
- ISSN
- 2590-1362
- PMID
- 37577264; PMC10422670
- Copyright note
- This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Grant note
- NSW Koala Strategy
- Organisation Unit
- University of the Sunshine Coast, Queensland; Thompson Institute; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99734298202621
- Output Type
- Journal article
Metrics
6 File views/ downloads
62 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Web Of Science research areas
- Immunology
- Medicine, Research & Experimental
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs from InCites